SCHEMBL6929222

SCHEMBL6929222

CCC1OC(=O)C(O)=C1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
LMNA P02545 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTPN1 P18031 4/20 0.37
ACP1 P24666 3/20 0.37
CDC25B P30305 3/20 0.37
RECQL P46063 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
PTPN2 P17706 1/20 0.37
DUSP3 P51452 1/20 0.37
HPSE Q9Y251 1/20 0.37
KDM4E B2RXH2 2/20 0.35
HSPD1 P10809 1/20 0.35
HSPE1 P61604 1/20 0.35
TST Q16762 1/20 0.35
BLM P54132 1/20 0.35
CES2 O00748 1/20 0.33
TP53 P04637 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6927981 0.83 MAPT (0.44) MAPTLMNAL3MBTL1PTPN1ACP1
SCHEMBL120920 0.80 MAPT (0.34) MAPTLMNAL3MBTL1PTPN1ACP1
SCHEMBL15962403 0.80 PTPN1 (0.36) MAPTPTPN1ACP1CDC25BRECQL
SCHEMBL13176951 0.80 PTPN1 (0.36) MAPTPTPN1ACP1CDC25BRECQL
SCHEMBL16198983 0.79 MAPT (0.48) MAPTLMNAL3MBTL1PTPN1ACP1
SCHEMBL592859 0.79 MAPT (0.48) MAPTLMNAL3MBTL1PTPN1ACP1
SCHEMBL2932077 0.79 MAPT (0.48) MAPTLMNAL3MBTL1PTPN1ACP1
SCHEMBL5351324 0.78 KDM4E (0.33) MAPTLMNAL3MBTL1PTPN1ACP1
SCHEMBL8116635 0.78 CES2 (0.51) MAPTLMNAL3MBTL1PTPN1ACP1
SCHEMBL9015275 0.77 MAPT (0.43) MAPTLMNAL3MBTL1PTPN1ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10328042-B2 Co-crystals of substituted glycine and uses thereof SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) 2019-06-25 US disclosed
US-20120052028-A1 CINNAMIC ACID ASCORBATES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-01 US disclosed
EP-1246811-B1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN LTD (GB) 2003-12-03 EP disclosed
US-6613919-B2 Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones OXIS ISLE OF MAN 2003-09-02 US disclosed
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones OXIS ISLE OF MAN 2003-04-03 US disclosed
EP-1246811-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS Isle of Man, Limited (GB) 2002-10-09 EP disclosed
WO-2001049671-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN, LIMITED (US) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10328042-B2 Co-crystals of substituted glycine and uses thereof PSEN1, PSEN2, GRIN2C MAPT 78/4885LMNA 3194/4885L3MBTL1 1875/4885
US-20120052028-A1 CINNAMIC ACID ASCORBATES PROC, C1S, NISCH MAPT 1785/4885LMNA 560/4885L3MBTL1 4650/4885
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones ADH1C, SRD5A2, SRD5A1 MAPT 4026/4885LMNA 633/4885L3MBTL1 4803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.